Market Failure? Lower Drug Prices Don't Improve Access In Rheumatoid Arthritis
Executive Summary
'Perverse incentives' guide US pricing for rheumatoid arthritis drugs, stakeholders say at policy roundtable convened by Institute for Clinical and Economic Review.